Paper

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

Published Dec 1, 2014 · M. R. Maleki-Yazdi, T. Kaelin, N. Richard

Respiratory medicine

124

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCTHighly Cited

Study Snapshot

Umeclidinium/vilanterol 62.5/25 mcg significantly improves lung function and quality of life in COPD patients compared to tiotropium 18 mcg, offering a new treatment option.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

References

Citations